TRVI Financials

Income Statement
MetricQ3 2026Q2 2026Q1 2026Q4 2025Q3 2025
Revenue
0
0
0
0
0
Cost of Revenue
0
0
0
0
0
Gross Profit
0
0
0
0
0
Operating Expenses
24.5M
+19.4%
20.5M
+37.5%
14.9M
+45.9%
10.2M
-26.6%
13.9M
R&D
19.1M
+25.8%
15.2M
+52.4%
9.9M
+60.5%
6.2M
-38.6%
10.1M
SG&A
5.4M
+1.2%
5.4M
+7.8%
5.0M
+23.4%
4.0M
+5.1%
3.8M
Operating Income
-24486000
-19.4%
-20509000
-37.5%
-14912000
-45.9%
-10220000
+26.6%
-13916000
EBITDA
-24445000
-19.4%
-20475000
-37.6%
-14878000
-46.0%
-10189000
+26.6%
-13878000
Net Income
-21452000
-20.5%
-17797000
-34.9%
-13192000
-58.6%
-8316000
+29.5%
-11802000
EPS (Basic)
$-0.13
-18.2%
$-0.11
-22.2%
$-0.09
-50.0%
$-0.06
+25.0%
$-0.08
EPS (Diluted)
$-0.13
-18.2%
$-0.11
-22.2%
$-0.09
-50.0%
$-0.06
+25.0%
$-0.08
Shares (Diluted)
159.7M
+2.0%
156.6M
+7.6%
145.6M
-0.2%
145.9M
+0.6%
145.1M
Trevi Therapeutics (TRVI) — Financials